SPONSORED BY SICA MEDIA AND DISSEMINATED ON BEHALF OF PHARMACYTE BIOTECH,  INC.*

Good Morning Market Enthusiast,

PMCB (Nasdaq: PMCB) isn’t moving like a biotech today. It’s moving like a sleeper that’s suddenly being shaken awake — and when that happens in micro-cap land, the moves can turn violent fast.

On paper, PMCB looks like one of the cleanest setups you’ll find in 2025. The company sits on ~$55 million in total assets, including ~$15.5 million in cash, and another $22+ million in preferred equity like TNF, plus holdings in names such as Femasys (FEMY). That’s real, tangible value, not blue-sky promises.

Yet the ticker is sitting in the single-digit millions for market cap — barely scratching $6–7M by current ranges. The disconnect is staggering. 

Observers live for setups where the chart lags the math, and PMCB is flashing one of the widest gaps we’ve seen all summer.

But this isn’t just about “cheap on paper.” The latest press releases and fresh action today signal that PMCB’s story is evolving right now — and momentum is starting to build. (2)(3)(4)

(1)

Here’s what you need to know:

⚡ Catalyst 1: A Balance Sheet That Outsizes the Ticker (2)(3)(4)

For most micro-caps, the story starts with hope. For PMCB, the story starts with math.
 

• Cash position: ~$15.5 million — already worth 2x today’s market cap.
• Portfolio: ~$22.47 million in preferred TNF stock + ~$7M+ in other public company stakes (including ~$5M in FEMY shares acquired in late 2023).
• Total assets: ~$55 million (10x the market value).
   

That’s before assigning any value at all to the biotech platform the company was originally built on. Even if you haircut the numbers to reflect FEMY’s price pullback since acquisition, the asset pile still dwarfs PMCB’s current tape.

The math gap is impossible to ignore. You’ve got a company that could, in theory, liquidate tomorrow and still return multiples of its current market cap. In micro-cap land, those setups don’t stay hidden for long.

⚡ Catalyst 2: Strategic Equity Bets with Built-In Torque (2)(3)(4)

PMCB hasn’t just been sitting on cash. It’s been deploying into strategic, asymmetric positions in other public companies.
 

• The $5M into Femasys (FEMY) in November 2023 was timed as the women’s health biotech was pivoting with FDA catalysts. While FEMY has since drifted lower, the equity provides optionality if the company executes.
• The $22.47M in TNF preferred stock locks in exposure to a vehicle with embedded upside — and TNF’s own value has shifted dramatically since PMCB first booked the line.
   

Here’s where it gets interesting: if either of these holdings rerates higher, PMCB’s balance sheet torque compounds immediately. The company’s value isn’t just static cash; it’s levered into catalysts across multiple tickers, giving it more ways to move than most single-asset micro-caps.

⚡ Catalyst 3: The Market Is Just Now Noticing (2)(3)(4)

Today’s tape proves it: PMCB is starting to move.

The press release cycle in 2025 has been steady, but this recent update has everyone finally looking up from their screens. PMCB’s float is thin. When you combine that with sudden volume spikes, you get the recipe for outsized swings — not weeks from now, but intraday.

Micro-caps like this often spend months forgotten, then explode once fresh attention collides with fundamentals that were hiding in plain sight. That moment of recognition is what seems to be playing out now with PMCB.

And once retail chatter heats up, it’s not uncommon for these dislocations to correct violently — sometimes in hours, not weeks.

⚡ Catalyst 4: Hidden Optionality in the Biotech Engine (2)(3)(4)

It’s easy to focus only on the cash and assets, but PMCB is still a biotech with a therapeutic platform in its back pocket.

Even though management has shifted emphasis toward capital deployment and strategic holdings, the Cell-in-a-Box® platform remains a call option embedded in the ticker. If licensing or new development progress were announced, that optionality could instantly change the narrative — stacking biotech upside on top of the already-mispriced balance sheet.

That’s the part people forget until it shows up in a headline. And by then, PMCB may already have doubled or tripled off its lows.

⚡ Catalyst 5: Perfect Setup for Retail-Driven Runs (2)(3)(4)

The final catalyst isn’t in the numbers — it’s in the setup.
 

• Float: Extremely thin, meaning even modest demand can trigger outsized price swings.
• Valuation gap: Assets outsize market cap by nearly 10-to-1.
• Newsflow: Press releases are hitting this month, and the latest one today has already started pulling in new eyes.
   

This is the exact DNA of past retail-driven micro-cap runs: thin float + hard catalyst + glaring disconnect. And PMCB is sitting right at the nexus.

Wrapping It Together

PMCB (Nasdaq: PMCB) is more than a biotech. It’s a mispriced asset bomb waiting for ignition.

The cash and assets alone justify multiples of today’s market value. Add in equity bets with built-in torque, an underappreciated biotech option, and a float that can barely absorb modest volume — and you’ve got the makings of a ticker that can go from forgotten to front-page fast.

Today’s action shows the fuse is lit. Whether it’s hours, days, or weeks before the full move plays out, PMCB is awake — check them out now!

Keep it locked.

To your success,

Max Masters

Co-founder, Market Tips Newsletter

Sources:
1. https://pharmacyte.com/
2. https://finance.yahoo.com/news/pharmacyte-biotech-inc-announces-7-131500097.html
3. https://finance.yahoo.com/quote/PMCB/
4. https://pharmacyte.com/news/
5. https://finance.yahoo.com/quote/PMCB/key-statistics/

Paid Promotion. Momentum Media LLC has been hired for a period beginning on 08/18/2025 and ending on 08/19/2025 (the “Campaign”) to publicly disseminate information about PharmaCyte Biotech, Inc. (PMCB:US). Momentum Media LLC has been compensated $10,000 and are owed an additional $0 for the Campaign. Please read Momentum Media LLC’s complete disclaimer at https://markettips.net/disclaimer/ which includes important information. Emojis, graphics and/or images used herein have no specific or implied meaning, and are used for artistic purposes only. Nothing contained herein is financial advice. Momentum Media LLC is not an analyst, stock broker, financial adviser or stock picker nor is it qualified to act in the capacity of any of the foregoing. Information herein is a paid advertisement and should not be relied upon as accurate or complete.